# PHKG2

## Overview
The PHKG2 gene encodes the phosphorylase kinase catalytic subunit gamma 2, a critical component of the phosphorylase kinase enzyme complex involved in glycogen metabolism. This protein functions as a kinase, facilitating the phosphorylation of glycogen phosphorylase, thereby playing a pivotal role in glycogen breakdown and energy release, particularly in liver and muscle tissues (Li2018PHKG2; Waheed2020Variability). The PHKG2 protein is part of a heterotetrameric complex that includes regulatory subunits, which modulate its activity (Burwinkel2003Severe). Mutations in the PHKG2 gene are linked to glycogen storage disease type IX, leading to significant clinical manifestations such as hepatomegaly and hypoglycemia due to impaired glycogenolysis (Kishnani2019Diagnosis; Gibson2021Characterization). The gene's role in cellular metabolism and its involvement in disease underscore its importance in both physiological and pathological contexts.

## Structure
The PHKG2 gene encodes the gamma subunit of phosphorylase kinase, a key enzyme in glycogen metabolism. The protein is composed of 406 amino acids, with its catalytic domain extending approximately between amino acids 24 and 290 (Burwinkel2003Severe). This domain is crucial for its kinase activity, which involves the phosphorylation of substrates. The PHKG2 protein is part of a larger hexadecameric complex, consisting of four subunits (α, β, γ, and δ), which form the quaternary structure of phosphorylase kinase (DavitSpraul2011Liver).

Mutations in PHKG2 often affect the catalytic domain, leading to severe phenotypes of liver glycogenosis. These mutations include missense, nonsense, splice-site, and frameshift mutations, which can significantly reduce enzyme activity (Burwinkel2003Severe). The protein may undergo post-translational modifications such as phosphorylation, which are typical for kinase proteins, although specific modifications for PHKG2 are not detailed in the context provided.

The PHKG2 gene also exhibits splice variants, which can result in different isoforms of the gamma subunit, potentially affecting its function and interaction within the phosphorylase kinase complex (Li2018PHKG2). These structural and functional aspects underscore the importance of PHKG2 in glycogen metabolism and its role in glycogen storage diseases.

## Function
The PHKG2 gene encodes the gamma subunit of phosphorylase kinase (PhK), a crucial enzyme in glycogen metabolism. In healthy human cells, PHKG2 plays a significant role in the regulation of glycogen breakdown by encoding the catalytic subunit of PhK, which is responsible for phosphorylating and activating glycogen phosphorylase. This activation is essential for converting glycogen into glucose-1-phosphate, a critical step in energy release, particularly in liver and muscle cells (Li2018PHKG2; Waheed2020Variability).

Phosphorylase kinase is a heterotetrameric enzyme composed of four subunits: α, β, γ, and δ. The gamma subunit, encoded by PHKG2, contains the active site necessary for the enzyme's catalytic activity (Burwinkel2003Severe). This subunit is vital for maintaining normal glycogen metabolism, preventing the accumulation of glycogen in the liver and ensuring proper energy homeostasis (BURWINKEL2000Phosphorylase).

In the cellular context, PHKG2 is active in the cytoplasm, where it influences metabolic responses and energy balance. Its function is crucial for maintaining normal blood glucose levels, especially during fasting or physical exertion, by facilitating the breakdown of glycogen stores (Burwinkel2003Severe).

## Clinical Significance
Mutations in the PHKG2 gene are associated with glycogen storage disease type IX (GSD IX), specifically subtypes IXc and IX γ2, which primarily affect liver function. These mutations lead to phosphorylase kinase (PhK) deficiency, resulting in impaired glycogen breakdown. Clinical manifestations include hepatomegaly, hypoglycemia, growth retardation, and elevated liver enzymes (Kishnani2019Diagnosis; Li2018PHKG2; Gibson2021Characterization). 

Patients with PHKG2 mutations often develop severe liver disease, progressing from fibrosis to cirrhosis, and in some cases, liver failure or hepatocellular carcinoma (Gibson2021Characterization; Kido2021A). The condition is autosomal recessive, and symptoms can manifest early in life, with some patients experiencing pronounced hypoglycemia requiring dietary management, such as high protein intake and uncooked cornstarch supplements (Kishnani2019Diagnosis; Gibson2021Characterization).

The mutation spectrum of PHKG2 includes missense and nonsense mutations, with common sites in exons 3 and 6 (Li2018PHKG2). These genetic alterations can lead to a more severe phenotype compared to other GSD IX subtypes, with significant clinical variability and potential progression to severe liver complications (DavitSpraul2011Liver; Massese2022Glycogen).

## Interactions
PHKG2, a catalytic subunit of phosphorylase kinase, is involved in various protein interactions that influence its function in glycogen metabolism and other cellular processes. It is part of a complex that includes regulatory subunits such as PHKA1, PHKA2, and PHKB, which are essential for its kinase activity (Galligan2014Proteomic). 

In the context of non-small cell lung cancer (NSCLC), PHKG2 interacts with the NRF2 transcription factor. NRF2 acts as a transcriptional repressor of PHKG2, and this interaction plays a significant role in regulating radiosensitivity through ferroptosis, an iron-dependent form of cell death. Inhibiting NRF2 can lead to increased expression of PHKG2, promoting ferritinophagy and enhancing radiosensitivity in NSCLC cells (Han2024Targeting). 

PHKG2 is also implicated in mitochondrial dysfunction following radiotherapy, characterized by changes in mitochondrial membrane potential and reactive oxygen species (ROS) levels. These effects are linked to its role in promoting ferroptosis and enhancing radiosensitivity in cancer cells (Han2024Targeting). 

Overall, PHKG2's interactions with other proteins and its involvement in cellular pathways highlight its potential as a therapeutic target in cancer treatment.


## References


[1. (Galligan2014Proteomic) Jeffrey T. Galligan, Gustavo Martinez-Noël, Verena Arndt, Sebastian Hayes, Thomas W. Chittenden, J. Wade Harper, and Peter M. Howley. Proteomic analysis and identification of cellular interactors of the giant ubiquitin ligase herc2. Journal of Proteome Research, 14(2):953–966, December 2014. URL: http://dx.doi.org/10.1021/pr501005v, doi:10.1021/pr501005v. This article has 44 citations and is from a peer-reviewed journal.](https://doi.org/10.1021/pr501005v)

[2. (Kishnani2019Diagnosis) Priya S. Kishnani, Jennifer Goldstein, Stephanie L. Austin, Pamela Arn, Bert Bachrach, Deeksha S. Bali, Wendy K. Chung, Areeg El-Gharbawy, Laurie M. Brown, Stephen Kahler, Surekha Pendyal, Katalin M. Ross, Laurie Tsilianidis, David A. Weinstein, and Michael S. Watson. Diagnosis and management of glycogen storage diseases type vi and ix: a clinical practice resource of the american college of medical genetics and genomics (acmg). Genetics in Medicine, 21(4):772–789, April 2019. URL: http://dx.doi.org/10.1038/s41436-018-0364-2, doi:10.1038/s41436-018-0364-2. This article has 83 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41436-018-0364-2)

[3. (Burwinkel2003Severe) Barbara Burwinkel, Terje Rootwelt, Eli Anne Kvittingen, Pranesh K Chakraborty, and Manfred W Kilimann. Severe phenotype of phosphorylase kinase-deficient liver glycogenosis with mutations in the phkg2 gene. Pediatric Research, 54(6):834–839, December 2003. URL: http://dx.doi.org/10.1203/01.PDR.0000088069.09275.10, doi:10.1203/01.pdr.0000088069.09275.10. This article has 60 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1203/01.PDR.0000088069.09275.10)

[4. (Han2024Targeting) Fushi Han, Shuzhen Chen, Kangwei Zhang, Kunming Zhang, Meng Wang, and Peijun Wang. Targeting nrf2/phkg2 axis to enhance radiosensitivity in nsclc. npj Precision Oncology, August 2024. URL: http://dx.doi.org/10.1038/s41698-024-00629-3, doi:10.1038/s41698-024-00629-3. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41698-024-00629-3)

[5. (Li2018PHKG2) Chunyun Li, Lihua Huang, Lang Tian, Jia Chen, Shentang Li, and Zuocheng Yang. Phkg2 mutation spectrum in glycogen storage disease type ixc: a case report and review of the literature. Journal of Pediatric Endocrinology and Metabolism, 31(3):331–338, January 2018. URL: http://dx.doi.org/10.1515/jpem-2017-0170, doi:10.1515/jpem-2017-0170. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.1515/jpem-2017-0170)

[6. (Waheed2020Variability) Nadia Waheed, Anjum Saeed, Sadaqat Ijaz, Zafar Fayyaz, Muhammad Nadeem Anjum, Yasir Zahoor, and Huma Arshad Cheema. Variability of clinical and biochemical phenotype in liver phosphorylase kinase deficiency with variants in the phosphorylase kinase (phkg2) gene. Journal of Pediatric Endocrinology and Metabolism, 33(9):1117–1123, July 2020. URL: http://dx.doi.org/10.1515/jpem-2019-0603, doi:10.1515/jpem-2019-0603. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1515/jpem-2019-0603)

[7. (BURWINKEL2000Phosphorylase) B. BURWINKEL. Phosphorylase kinase deficient liver glycogenosis: progression to cirrhosis in infancy associated with phkg2 mutations (h144y and l225r). Journal of Medical Genetics, 37(5):376–377, May 2000. URL: http://dx.doi.org/10.1136/jmg.37.5.376, doi:10.1136/jmg.37.5.376. This article has 24 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1136/jmg.37.5.376)

[8. (DavitSpraul2011Liver) Anne Davit-Spraul, Monique Piraud, Dries Dobbelaere, Vassili Valayannopoulos, Philippe Labrune, Dalila Habes, Olivier Bernard, Emmanuel Jacquemin, and Christiane Baussan. Liver glycogen storage diseases due to phosphorylase system deficiencies: diagnosis thanks to non invasive blood enzymatic and molecular studies. Molecular Genetics and Metabolism, 104(1–2):137–143, September 2011. URL: http://dx.doi.org/10.1016/j.ymgme.2011.05.010, doi:10.1016/j.ymgme.2011.05.010. This article has 39 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ymgme.2011.05.010)

[9. (Gibson2021Characterization) Rebecca A. Gibson, Jeong-A Lim, Su Jin Choi, Leticia Flores, Lani Clinton, Deeksha Bali, Sarah Young, Aravind Asokan, Baodong Sun, and Priya S. Kishnani. Characterization of liver gsd ix γ2 pathophysiology in a novel phkg2/ mouse model. Molecular Genetics and Metabolism, 133(3):269–276, July 2021. URL: http://dx.doi.org/10.1016/j.ymgme.2021.05.008, doi:10.1016/j.ymgme.2021.05.008. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ymgme.2021.05.008)

[10. (Massese2022Glycogen) Miriam Massese, Francesco Tagliaferri, Carlo Dionisi-Vici, and Arianna Maiorana. Glycogen storage diseases with liver involvement: a literature review of gsd type 0, iv, vi, ix and xi. Orphanet Journal of Rare Diseases, June 2022. URL: http://dx.doi.org/10.1186/s13023-022-02387-6, doi:10.1186/s13023-022-02387-6. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13023-022-02387-6)

[11. (Kido2021A) Jun Kido, Hiroshi Mitsubuchi, Takehisa Watanabe, Keishin Sugawara, Hideo Sasai, Toshiyuki Fukao, and Kimitoshi Nakamura. A female patient with gsd ixc developing multiple and recurrent hepatocellular carcinoma: a case report and literature review. Human Genome Variation, December 2021. URL: http://dx.doi.org/10.1038/s41439-021-00172-8, doi:10.1038/s41439-021-00172-8. This article has 4 citations.](https://doi.org/10.1038/s41439-021-00172-8)